Adagene CEO Peter Luo details equity holdings
Adagene Inc. Chief Executive Officer Peter Luo filed an initial statement of beneficial ownership, detailing his existing equity positions in the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Adagene Inc. Chief Executive Officer Peter Luo filed an initial statement of beneficial ownership, detailing his existing equity positions in the company. The filing lists direct holdings of ordinary shares, multiple incentive stock options to acquire ordinary shares at exercise prices ranging from $1.04 to $13.85 with expirations between 2031 and 2036, and restricted stock units granted under Adagene’s equity plans. It also discloses additional options, RSUs, and ordinary shares held indirectly through his spouse. The document reports holdings only and does not show any purchases or sales.
Insider Trade Summary
20 transactions reported
Mixed
20 txns
Insider
Luo Peter
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Incentive Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
Holdings After Transaction:
Incentive Stock Option (Right to Buy) — 4,145,234 contracts (Direct);
Incentive Stock Option (Right to Buy) — 761,252 contracts (Indirect, By Spouse);
Ordinary Shares — 93,264 shares (Direct);
Ordinary Shares — 31,021 shares (Indirect, By Spouse);
Restricted Stock Unit — 168,750 shares (Direct);
Restricted Stock Unit — 75,000 shares (Indirect, By Spouse)
Footnotes (18)
- F1. 168,750 of Restricted Stock Units ("RSUs") granted under the Adagene Inc. 2021 Performance Incentive Plan. 56,250 of RSUs shall vest on each of the following dates: 7/23/2026, 7/23/2027, and 7/23/2028.
- F2. 75,000 of RSUs granted under the Adagene Inc. 2021 Performance Incentive Plan. 25,000 of RSUs should be vested annually on each of the following dates: 7/23/2026, 7/23/2027, and 7/23/2028.
- F3. 287,415 of time-based incentive stock options granted under the Adagene Inc. Second Amended and Restated Share Incentive Plan (pre-IPO), and all such option are fully vested and exercisable.
- F4. 50,000 of performance-based stock options granted under the Adagene Inc. 2021 Performance Incentive Plan, and all such option are fully vested and exercisable.
- F5. 500,000 of time-based stock option granted on 5/3/2023 under the Adagene Inc. 2021 Performance Incentive Plan. The options shall become exercisable with respect to 25% of the options on each of the first four anniversaries of the grant date. Accordingly, 250,000 shares subject to this option are vested and exercisable.
- F6. 500,000 of time-based stock option granted on 12/27/2023 under the Adagene Inc. 2021 Performance Incentive Plan. The options shall become exercisable with respect to 25% of the options on each of the first four anniversaries of the grant date. Accordingly, 250,000 shares subject to this option are vested and exercisable.
- F7. 822,819 of time-based stock option granted on 11/17/2024 under the Adagene Inc. 2021 Performance Incentive Plan. 50% of the options shall vest on 6/30/2025 and 6/30/2026, respectively; accordingly, 411,410 shares subject to this option are vested and exercisable.
- F8. 450,000 of time-based stock option granted on 12/24/2024 under the Adagene Inc. 2021 Performance Incentive Plan. The options shall become exercisable with respect to 25% of the options on each of the first four anniversaries of the grant date. Accordingly,112,500 shares subject to this option are vested and exercisable.
- F9. 735,000 of time-based stock option granted on 6/5/2025 under the Adagene Inc. 2021 Performance Incentive Plan, and shall become exercisable with respect to 25% of the stock options on each of the first four anniversaries of the grant.
- F10. 800,000 of time-based stock option granted on 2/5/2026 under the Adagene Inc. 2021 Performance Incentive Plan, and shall become exercisable with respect to 25% of the stock options on each of the first four anniversaries of the grant.
- F11. 45,980 of time-based incentive stock options granted under the Adagene Inc. Second Amended and Restated Share Incentive Plan (pre-IPO), and all such shares subject to this option are fully vested and exercisable.
- F12. 2,250 of performance-based stock options granted under the Adagene Inc. 2021 Performance Incentive Plan, and all such shares subject to this option are fully vested and exercisable.
- F13. 100,000 of time-based stock option granted on 5/9/2023 under the Adagene Inc. 2021 Performance Incentive Plan. The options shall become exercisable with respect to 25% of the options on each of the first four anniversaries of the grant date. Accordingly, 50,000 shares subject to this option are vested and exercisable.
- F14. 100,000 of time-based stock option granted on 12/18/2023 under the Adagene Inc. 2021 Performance Incentive Plan. The options shall become exercisable with respect to 25% of the options on each of the first four anniversaries of the grant date. Accordingly, 50,000 shares subject to this option are vested and exercisable.
- F15. 152,322 of time-based stock option granted on 11/17/2024 under the Adagene Inc. 2021 Performance Incentive Plan. 50% of the options shall vest on 6/30/2025 and 6/30/2026, respectively; accordingly, 76,161 shares subject to this option became vested and exercisable.
- F16. 80,000 of time-based stock option granted on 12/24/2024 under the Adagene Inc. 2021 Performance Incentive Plan. The options shall become exercisable with respect to 25% of the options on each of the first four anniversaries of the grant date. Accordingly, 20,000 shares subject to this option are vested and exercisable.
- F17. 130,700 of time-based stock option granted on 6/5/2025 under the Adagene Inc. 2021 Performance Incentive Plan, and became exercisable with respect to 25% of the stock options on each of the first four anniversaries of the grant.
- F18. 150,000 of time-based stock option granted on 2/5/2026 under the Adagene Inc. 2021 Performance Incentive Plan, and became exercisable with respect to 25% of the stock options on each of the first four anniversaries of the grant.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Peter Luo’s Form 3 filing for Adagene (ADAG) disclose?
The Form 3 shows CEO Peter Luo’s existing equity holdings in Adagene Inc., including ordinary shares, stock options, and restricted stock units. It provides a baseline of his direct and spouse-held indirect positions at the time he became a reporting insider.
Does the Adagene (ADAG) Form 3 show any insider buying or selling by Peter Luo?
The filing does not show any insider buying or selling. It consists entirely of holding entries, meaning it records Luo’s and his spouse’s current ownership of ordinary shares, options, and RSUs rather than new market or option exercise transactions.
What stock option positions does Peter Luo report in Adagene (ADAG)?
Luo reports several incentive and time-based stock options over ordinary shares with exercise prices including $13.85, $5.60, $1.04, $1.33, $1.73, $1.55, $1.408, and $2.032, expiring between 2031 and 2036, some fully vested and others vesting over four years.
What restricted stock units (RSUs) are reported in the Adagene (ADAG) Form 3?
The filing notes 168,750 RSUs granted under Adagene’s 2021 Performance Incentive Plan, vesting in three equal tranches of 56,250 on 7/23/2026, 7/23/2027, and 7/23/2028, plus 75,000 RSUs for his spouse vesting 25,000 each on the same dates.
How much of Peter Luo’s Adagene (ADAG) equity is held indirectly through his spouse?
The Form 3 shows indirect holdings “By Spouse,” including stock options over ordinary shares such as 45,980 and 100,000-share grants at various exercise prices, as well as 31,021 ordinary shares and 75,000 RSUs. These positions are associated with his spouse rather than held directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
